Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting
Zimmer Biomet announced the commercial launch of its new Z1™ Femoral Hip System at the 2024 AAHKS Annual Meeting. The Z1 System, featuring a triple-taper design, integrates with the company's G7® Acetabular System to provide a comprehensive hip arthroplasty solution. The system offers collared and collarless options, three distinct neck options, and uses a single streamlined instrument tray. The company also highlighted its recent acquisition of OrthoGrid Systems, adding AI-powered surgical assistance applications to its portfolio. Clinical data on the G7 Acetabular System's safety and durability will be presented at the meeting.
Zimmer Biomet ha annunciato il lancio commerciale del suo nuovo Z1™ Femoral Hip System durante l'Annual Meeting AAHKS 2024. Il Sistema Z1, dotato di un design a triplo cono, si integra con il G7® Acetabular System dell'azienda per fornire una soluzione completa per l'artroplastica dell'anca. Il sistema offre opzioni con e senza collare, tre diverse opzioni di collo e utilizza un'unica offerta di strumenti semplificata. L'azienda ha anche evidenziato l'acquisizione recente di OrthoGrid Systems, che aggiunge applicazioni di assistenza chirurgica potenziate dall'IA al proprio portafoglio. I dati clinici sulla sicurezza e durevolezza del G7 Acetabular System saranno presentati durante l'incontro.
Zimmer Biomet anunció el lanzamiento comercial de su nuevo Z1™ Femoral Hip System en la Reunión Anual AAHKS 2024. El Sistema Z1, que cuenta con un diseño de triple conicidad, se integra con el G7® Acetabular System de la compañía para proporcionar una solución integral para la artroplastia de cadera. El sistema ofrece opciones con y sin collar, tres opciones de cuello distintas y utiliza una única bandeja de instrumentos optimizada. La empresa también destacó su reciente adquisición de OrthoGrid Systems, que añade aplicaciones de asistencia quirúrgica impulsadas por IA a su cartera. Se presentarán datos clínicos sobre la seguridad y durabilidad del sistema G7 Acetabular en la reunión.
Zimmer Biomet는 2024 AAHKS 연례 회의에서 새로운 Z1™ 대퇴부 엉덩이 시스템의 상업적 출시를 발표했습니다. Z1 시스템은 삼중 테이퍼 디자인을 특징으로 하며, 회사의 G7® 비구 시스템과 통합되어 포괄적인 엉덩이 인공관절 수술 솔루션을 제공합니다. 이 시스템은 칼라가 있는 옵션과 없는 옵션, 세 가지 뚜렷한 목 옵션을 제공하며 단일 간소화된 도구 트레이를 사용합니다. 또한 회사는 OrthoGrid Systems의 최근 인수를 강조하며 AI 기반의 수술 지원 응용 프로그램을 포트폴리오에 추가했습니다. G7 비구 시스템의 안전성과 내구성에 대한 임상 데이터가 회의에서 발표될 예정입니다.
Zimmer Biomet a annoncé le lancement commercial de son nouveau Z1™ Femoral Hip System lors de la réunion annuelle AAHKS 2024. Le système Z1, avec un design en triple conicité, s'intègre au G7® Acetabular System de l'entreprise pour fournir une solution complète pour l'arthroplastie de la hanche. Le système propose des options avec et sans col, trois options de cou distinctes et utilise un plateau d'instruments unique et rationalisé. L'entreprise a également souligné son acquisition récente de OrthoGrid Systems, ajoutant des applications d'assistance chirurgicale alimentées par IA à son portefeuille. Des données cliniques sur la sécurité et la durabilité du système G7 Acetabular seront présentées lors de la réunion.
Zimmer Biomet hat den kommerziellen Launch seines neuen Z1™ Femoral Hip Systems auf dem 2024 AAHKS Jahresmeeting angekündigt. Das Z1-System, das ein dreifach verjüngtes Design aufweist, integriert sich mit dem G7® Acetabular System des Unternehmens, um eine umfassende Lösung für die Hüftarthroplastik anzubieten. Das System bietet Optionen mit und ohne Kragen, drei verschiedene Nackenvarianten und verwendet ein einziges, optimiertes InstrumentenTableau. Das Unternehmen hob auch die kürzliche Übernahme von OrthoGrid Systems hervor, die KI-gestützte chirurgische Assistenzanwendungen in sein Portfolio aufnimmt. Klinische Daten zur Sicherheit und Haltbarkeit des G7 Acetabular Systems werden auf dem Meeting vorgestellt.
- Launch of new Z1™ Femoral Hip System expanding product portfolio
- Strategic acquisition of OrthoGrid Systems strengthening technological capabilities
- Integration capabilities between Z1 System and existing G7® Acetabular System
- Streamlined instrument tray reducing processing and sterilization costs
- None.
Insights
The launch of the Z1™ Femoral Hip System represents an incremental product advancement rather than a transformative innovation. While the triple-taper design offers improved stability features and surgical efficiency through streamlined instrumentation, its immediate financial impact will likely be modest. The system's integration with the existing G7® Acetabular System suggests a strategic focus on portfolio completeness rather than market disruption.
The acquisition of OrthoGrid Systems adds valuable AI-powered surgical guidance capabilities, particularly for cup positioning and leg length measurements. This technology integration, combined with the HAMMR™ automated impaction system, positions ZBH competitively in the growing surgical automation market. However, adoption rates for new orthopedic technologies typically follow a gradual curve due to surgeon learning curves and institutional budget cycles.
The pending clinical data presentations on metal ion levels and survivorship of the G7® system will be important for market acceptance and potential insurance coverage decisions.
The integration of AI-powered surgical assistance through OrthoGrid Hip AI® represents a significant technological advancement in orthopedic surgery. The system's ability to provide real-time fluoroscopy-based guidance for cup positioning and leg length measurements addresses critical surgical precision needs. When combined with the HAMMR™ automated impaction system, this creates a comprehensive digital ecosystem that could reduce surgical variability and improve outcomes.
The technology stack shows a clear strategic focus on surgical workflow optimization and precision. However, the market impact will depend on factors like integration capabilities with existing hospital systems, training requirements and cost-effectiveness compared to traditional methods. The success of this digital transformation initiative will be measured by surgeon adoption rates and clinical outcome improvements.
Company's Booth Spotlights Comprehensive Hip Portfolio and Enabling Technologies Including OrthoGrid Hip AI® and HAMMR™ Automated Hip Impaction System
"We are excited to share our robust hip portfolio, anchored by our new triple-taper femoral stem, Z1, and our well-established G7 Acetabular System," said Ivan Tornos, President and Chief Executive Officer of Zimmer Biomet. "Through a series of strategic acquisitions and in-house innovations, we've curated a diversified portfolio of hip implant solutions and innovative enabling technologies that provide surgeons with a wide array of options designed to address efficiency, accuracy and customization with a goal to improve overall surgical outcomes for patients."
The Z1 System is tapered in three planes, designed to provide initial axial and rotational stability, as well as long-term stability across a range of femoral anatomies. The system includes collared and collarless options for cementless applications and offers three distinct neck options to manage a variety of patient anatomies. Offered with a single streamlined instrument tray, the Z1 System minimizes the instrument footprint and reduces processing and sterilization burden.
Dr. Jesse Otero of OrthoCarolina, and Dr. Jonathan Yerasimides of Louisville Hip & Knee Institute, performed the first patient cases using the Z1 System.
"My first experience with the Z1 triple-taper femoral stem with the G7 Acetabular System can be summarized as the easiest and most natural implantation I have experienced," said Dr. Otero. Dr. Yerasimides added, "Z1 was simple and intuitive to use, and offers significant options and more versatility than earlier stems."
"Building on the success of our G7 Acetabular System, we delivered the Z1 System to address demand for a versatile and adaptable triple-taper femoral stem that allows surgeons to customize care for a broad range of hip arthroplasty patients," said Louis Galrao, President, Hips at Zimmer Biomet. "The Z1 and G7 systems are enhanced by our curated suite of enabling technologies, which are designed to complement a variety of surgical approaches and workflows to make AI-, robotic- and mixed reality-powered surgical navigation and guidance accessible and approachable for more surgeons and care teams."
Earlier this month, Zimmer Biomet further strengthened its hip portfolio with the acquisition of OrthoGrid Systems, Inc. and its multiple FDA-cleared, AI-powered, fluoroscopy-based surgical assistance applications, including OrthoGrid Hip AI®. OrthoGrid Hip AI delivers intuitive and instantaneous intra-operative guidance to assist the surgeon in achieving the desired surgical outcomes for cup positioning and leg length,1 and offset. OrthoGrid Hip AI is the newest addition to Zimmer Biomet's suite of enabling technologies for hip procedures which include HAMMR™, an adjustable and ergonomic automated impaction device that allows a surgeon to perform a total hip replacement with minimal to no mallet use.
Zimmer Biomet Activities at 2024 AAHKS Annual Meeting
At Booth #1100, Zimmer Biomet will display the Z1 and G7 systems, along with HAMMR, OrthoGrid Hip AI and its mixed reality and robotic technologies for hip procedures. In addition, data from three clinical studies, supported by Zimmer Biomet, will be presented in e-poster sessions*:
- Metal Ion Levels in Patients Undergoing Hip Arthroplasty with the G7® Dual Mobility System (Poster # 228; Lead Author: Krishna R. Tripuraneni, M.D.)
- Short- to Mid-Term Clinical Outcomes and Survivorship of a Porous Plasma-Sprayed Limited Hole Acetabular Shell (Poster # 227; Lead Author: Krishna R. Tripuraneni, M.D.)
- Is Change in Walking Asymmetry Correlated with Changes in Quality of Life in Patients Undergoing Total Joint Arthroplasty? (Poster # 206; Lead Author: Adolph V. Lombardi, Jr., M.D., FACS)
To learn more about Zimmer Biomet's hip portfolio, including the Z1 Femoral Hip System, visit www.zimmerbiomet.com/hip.
* Data results from accepted poster presentations are embargoed by AAHKS until Friday, November 8, 2024. Visit https://meeting.aahks.org/ to view the posters. |
About the Company
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the
References
1. Cardenas JM, Gordon D, Waddell BS, Kitziger KJ, Peters PC Jr, Gladnick BP. Does Artificial Intelligence Outperform Humans Using Fluoroscopic-Assisted Computer Navigation for Total Hip Arthroplasty? Arthroplast Today. 2024 May 27;27:101410. doi: 10.1016/j.artd.2024.101410. PMID: 38840694; PMCID: PMC11150909.
Media | Investors | |
Heather Zoumas-Lubeski 445-248-0577 heather.zoumaslubeski@zimmerbiomet.com
| David DeMartino 646-531-6115 david.demartino@zimmerbiomet.com
Zach Weiner | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-to-debut-new-z1-femoral-hip-system-and-clinical-data-on-g7-acetabular-system-at-2024-aahks-annual-meeting-302288101.html
SOURCE Zimmer Biomet Holdings, Inc.
FAQ
What is the new Z1™ Femoral Hip System announced by Zimmer Biomet (ZBH)?
When will Zimmer Biomet (ZBH) launch the Z1™ Femoral Hip System commercially?
What recent acquisition did Zimmer Biomet (ZBH) complete to enhance its hip portfolio?
What clinical data will Zimmer Biomet (ZBH) present at the 2024 AAHKS meeting?
